About 1/3 of those who’ve experienced eye infections as a result of the use of Bausch & Lomb’s ReNu eye contact solution are schedule to undergo corneal transplants. These new findings will be published in the Journal of the American Medical Association at the end of this month.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.